The capsid proteins of adenovirus serotype 5 (Ad5) 
Introduction
Growing concerns about gene therapy vector safety have spurred the ongoing development of physically targeted gene delivery vehicles. Among the advantages to targeting gene therapy is the lack of undesirable delivery to tissues other than the target tissue. Additionally, physical targeting should require lower doses of vector in comparison to an untargeted vector, and presumably, reduce the immunogenicity and toxicity of the vector.
Despite the potent immune response elicited by adenovirus vectors, 1,2 the highly efficient cell entry mechanism of the virus remains a desirable feature for gene delivery to both dividing and nondividing cells. Particularly, the cell binding and entry functions imparted by the fiber and penton capsid proteins of adenovirus serotype 5 (Ad5) are a major reason why adenoviruses continue to be widely used as vehicles for gene transfer. 3, 4 The antenna-like fiber proteins that protrude from each vertex of the icosahedral-shaped viral capsid bind with high affinity to ubiquitous cell surface Coxsackievirus adenovirus receptor (CAR) proteins. 5 This interaction initiates the infection mechanism of the virus, and is followed by the binding of the homopentameric penton base proteins, which lie at the base of each fiber, to cell surface integrins. 6 Integrin receptor-mediated endocytosis provides the cellular entry of the virus, but traps it in cellular endosomes. Endosome escape appears to be mediated by the penton, thus allowing entry of the virus to the cytosol. 7, 8 Presumed less toxic and immunogenic, nonviral vectors have been designed to mimic the receptor-mediated cell entry of adenoviruses. Early attempts to deliver genes by nonviral receptor-mediated endocytosis had fallen short of the goal of effective gene transfer, mainly because of the lack of cellular endosome escape. The inclusion of viral fusogenic peptides or endosomolytic agents with nonviral vectors has enhanced the gene delivery capacity of nonviral systems. [9] [10] [11] The adenovirus penton protein has been used for such a purpose. We have previously shown that a recombinant penton protein containing a decalysine sequence (PBK10) can bind DNA and mediate gene delivery into cells in culture in the absence of whole virus. 12 This delivery appeared to be mediated mainly through integrin receptor binding. When mixed at optimized ratios with plasmid DNA and the DNA condensing agent, protamine, effective gene delivery complexes were formed (PBK10/ protamine/plasmid DNA) and have been designated 3PO. Here we describe the production of a targeted penton protein (HerPBK10) containing a receptor-specific ligand to direct the binding of similar complexes to certain breast cancer cells.
The ligand protein used here is the receptor-binding domain of heregulin-α. This ligand binds with high affinity to heterodimers of HER2/3 or HER2/4 receptor subunits, which are overexpressed on certain mammary tumor cell lines. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] The binding kinetics between heregulin isomers and their target receptors have been well characterized using classical receptor binding techniques, and the internalization activities of the receptor subunits have been studied. [23] [24] [25] [26] [27] [28] We have previously shown that the heregulin ligand is rapidly internalized after binding to MDA-MB-453 human breast cancer cells. 29 Here we show that by appending the heregulin ligand to the recombinant penton protein, we can direct the delivery of conjugated plasmid DNA specifically to these breast cancer cells by way of heregulin receptor binding and internalization, while preserving the endosomolytic function of the penton which enhances transduction efficiency.
Results

Description and bacterial production of recombinant proteins
We constructed recombinant genes encoding several specific proteins (Figure 1a) . One of these constructs encodes the wild-type Ad5 penton (PB). A second construct encodes the Ad5 penton protein containing a carboxy (C)-terminal fusion of 10 lysines for binding DNA (PBK10). A third construct adds an amino (N)-terminal cell specific ligand to PBK10 to produce the targeted fusion protein, HerPBK10. We have also made the ligand alone (Her; also known as eHRG) 29 and as a C-terminal decalysine fusion protein (HerK10). Additionally, the ligand was produced as an N-terminal fusion to green fluorescent protein (GFP-Her; also known as GFP-eHRG). 29 We have previously shown that PB, PBK10, and Her can be produced in bacteria as soluble proteins.
12,29 Using a similar bacterial expression system, we produced HerPBK10 and HerK10. The ligand peptide used here is derived from the receptor binding domain of heregulin and contains an EGF-like motif that confers binding specificity to HER2-containing receptors. 23, 30 The version of ligand presented here has successfully directed the cell-specific binding of retroviral vectors when genetically engineered into the viral envelope. 31 We have also previously shown that heregulin receptor binding by this peptide is not impaired when fused to foreign sequences, such as GFP. 29 Polyclonal antiserum specific to Ad5 capsid proteins recognizes all three penton proteins (HerPBK10, PBK10 and PB), thus confirming their identities (Figure 1b) . Additional control proteins, Her, HerK10 and GFP-Her (not shown) were also highly expressed in bacteria and could be recognized by antibodies directed against the recombinant proteins. All proteins migrate at their expected molecular weights under denaturing conditions (Figure 1b) . The polylysine tag of HerK10 adds 10 additional amino acids to the Her segment, therefore the molecular weight of HerK10 is only about 1 kDa higher than Her.
HerPBK10 binds DNA
The polylysine tracts encoded by the recombinant penton constructs, PBK10 and HerPBK10, should impart DNA binding function to the fusion proteins by interacting with the negatively charged phosphate backbone of nucleic acids. To determine DNA binding ability, increasing concentrations of protein were incubated with constant amounts of a 5 kb plasmid DNA (pGFPemd-cmv), and the resulting effect on DNA mobility analyzed on an agarose gel. At concentrations where the amount of polylysine completely binds, and thus neutralizes all of the DNA, the plasmid appears immobilized on the gel. We have previously shown that PBK10 immobilizes the plasmid at the predicted protein-to-DNA (w/w) ratio of 22. 12 The predicted ratio of HerPBK10 to plasmid to produce the same effect is 29, and our results agree with this prediction (Figure 2b ). HerK10 exhibits a similar DNA mobility retardation pattern (Figure 2c) . Interestingly, the same amount of HerPBK10 to neutralize a 5 kb plasmid also neutralizes a DNA ladder (Figure 2a 
HerPBK10 binds heregulin receptors
The human breast cancer cell line, MDA-MB-453, which overexpresses HER2-containing receptors, was used to test receptor binding of HerPBK10. Receptor binding Gene Therapy activity was determined by an established assay that uses fluorescence activated cell sorting (FACS) to measure the amount of heregulin ligand required to displace the fluorescently tagged heregulin ligand, GFP-Her. 29 FACS analysis of MDA-MB-453 cells bound by GFP-Her are two orders of magnitude brighter than untreated cells (Figure 3a) . A 10-fold higher concentration of non GFPtagged Her reduces this fluorescence by nearly 95% (Figure 3c and g ). The Ad5 knob protein, which we produced and purified from E. coli similar to our other recombinant proteins, is used here as a nonspecific competitor. A 10-fold higher concentration of the knob pro- tein has no effect on cell fluorescence, as previously established (Figure 3b and g ). Increasing concentrations of HerPBK10 29 ( Figure 3d and g) and HerK10 (Figure 3f and g) proteins, produce reductions in cell fluorescence similar to that produced by Her, as measured by FACS assay, suggesting that the receptor binding of HerPBK10 is unchanged from that of free heregulin ligand. In addition, the incubation of pGFPemd-cmv plasmid with HerPBK10 has no effect on the ability of HerPBK10 to compete away cell fluorescence (Figure 3e ), indicating that DNA binding does not interfere with receptor binding activity.
Protamine protects HerPBK10/DNA complexes from serum protease degradation
We have found previously that the addition of protamine to PBK10/DNA complexes protects the plasmid from serum nuclease activity and enhances gene delivery to cells in serum-containing culture medium without overriding the receptor-specific binding of the complexes. 12 To confirm the ability of protamine to protect HerPBK10-bound DNA, we incubated HerPBK10/DNA complexes formed at a standardized protein to DNA (w/w) ratio of 3 with increasing concentrations of protamine in the presence of 20% active serum. Complexes that are sensitive to nuclease activity are detected by the conversion of the plasmid from the supercoiled form to the open circle form, as described elsewhere. 32 In the presence of serum, nearly all of the plasmid DNA, whether in the presence or absence of HerPBK10, is converted to nicked forms by 30 min at 37°C (Figure 4 ). However, adding increasing concentrations of protamine preserves supercoiled DNA in the presence of active serum for up to 45 min ( Figure 4) . A protamine to DNA ratio (w/w) of 7 assures complete protection of the plasmid from nuclease-induced degradation.
HerPBK10 mediates gene delivery to breast cancer cells in culture
To test the gene delivery capacity of complexes formed between HerPBK10, DNA and protamine, the pGFPemdcmv reporter plasmid was used. We first performed these experiments in the absence of serum to determine the ratios of DNA to proteins required for optimal gene delivery. HerPBK10/DNA complexes formed at a protein to DNA (w/w) ratio of 3 were incubated with increasing concentrations of protamine as described earlier. MDA-MB-453 human breast cancer cells were exposed to these complexes and assayed 3 days after treatment for the expression of GFP.
In the absence of HerPBK10, transduction is nearly undetectable at all of the protamine concentrations that were tested (Figure 5a ). In the presence of HerPBK10, increasing the concentration of protamine from 0 to 7 g of protamine per g of DNA enhances the green fluorescence from 0 to 6% GFP-positive cells (Figure 5a) . A protamine to DNA w/w ratio greater than 7 reduces transduction to 3% GFP-positive cells, presumably by competing with HerPBK10 for DNA binding. Lipofectin, which was used as a nonspecific transduction control, produced 62 ± 2.6% GFP-positive cells. The maximum numbers of green fluorescent cells were detectable by 4 days after treatment (Figure 5a ) and remained detectable up to 6 days after treatment (not shown). In subsequent assays, complexes were formed at a HerPBK10 to DNA (w/w) ratio of 3 and a protamine to DNA (w/w) ratio of 7, and will be referred to hereinafter as H2PO.
H2PO can also mediate the delivery and expression of a luciferase gene from the plasmid, pGL3 ( Figure 6 ). Increasing the concentration of HerPBK10 from 0 to 5 ng in H2PO complexes containing pGL3 enhances the luminescence detected in transduced MDA-MB-453 cells by up to 34-fold over protamine alone. In the absence of HerPBK10, delivery of pGL3 by protamine alone produces negligible luciferase activity at all of the protamine concentrations that were tested. Cells treated with lipofectin produced almost eight times the luminescence of cells treated with H2PO (not shown).
We next examined the ability of H2PO to mediate similar levels of gene delivery in the presence of 1 and 10% serum, respectively. DNA complexed with protamine alone produces nearly undetectable gene delivery both in the absence and presence of serum (Figure 5b ). H2PO enhances this delivery by nearly 20-fold in the absence of serum (Figure 5b) . Importantly, similar levels of gene delivery by H2PO are observed in the presence of either 1 or 10% serum (Figure 5b) . Thus, whereas the addition of protamine to the complex appears to mediate a protec- tive effect, HerPBK10 is still required for enhanced levels of gene delivery.
HerPBK10-mediated gene delivery is specific and requires the penton moiety
To test the specificity of H2PO-mediated gene delivery, free heregulin protein (Her) was used as a competitor for heregulin receptor binding on MDA-MB-453 human breast cancer cells. In the presence of eight-fold higher concentrations of Her compared with HerPBK10, relative transduction (as measured by GFP fluorescence) is reduced by nearly 90% (Figure 5c ). We also tested H2PO transduction of cells that do not express high levels of heregulin receptors. H2PO-mediated transduction of MDA-MB-231 cells, which express low to undetectable levels of HER-2 and -4, 31 produces only 12% of the GFPfluorescence of MDA-MB-453 cells (Figure 5c ). Together, these findings suggest that gene delivery by H2PO is mediated predominantly by specific binding to the heregulin receptor.
To determine whether integrins, the natural receptors for the penton protein, are also involved in mediating H2PO transduction, an RGD-containing peptide (GRGDTP) was used as a competitor for α v integrin receptor binding. We have shown previously that similar complexes formed between PBK10, DNA and protamine (3PO) mediate gene delivery by integrin binding that is competitively inhibited by GRGDTP. 12 Interestingly, in this case, even at a concentration up to 100-fold higher than HerPBK10, GRGDTP produces no significant effect on H2PO-mediated gene delivery (Figure 5c ).
Taken together, these findings suggest that cell binding by H2PO is not mediated by the integrin binding motif found on the penton moiety of HerPBK10, but rather by the heregulin receptor binding domain, Her. This also suggests that the requirement for integrin receptormediated endocytosis may be substituted by internalization via the heregulin receptor. The requirement for the heregulin domain to enhance targeted delivery is further demonstrated by comparison with the use of PBK10 as a targeting moiety in 3PO complexes exposed to MDA-MB-453 cells. The delivery of the same concentration of a reporter plasmid to MDA-MB-453 cells by HerPBK10 exceeds that of PBK10 by more than 10-fold (Figure 5c ).
The critical importance of the penton moiety is underscored when it is removed from the HerPBK10 construct to create the deletion mutant, HerK10. Whereas this protein binds DNA and heregulin receptors in a similar fashion to HerPBK10 (Figure 2c and Figure 3f and g ), complexes made between HerK10, pGFPemd-cmv, and protamine produced 97% less green fluorescence than H2PO, and did not enhance transduction over protamine and DNA alone (Figure 5c ). As competition for integrin binding by the RGD peptide did not appear to significantly affect overall transduction levels, it is plausible that the penton domain in HerPBK10 is required for the lysis of the endosomal vesicle after endocytosis.
To confirm whether H2PO is capable of endosome escape, H2PO was added to cells in the presence or absence of the acidotropic reagent, chloroquine. Although chloroquine inhibits endosome acidification, it also accumulates in intracellular vesicles, thereby inducing osmotic swelling and release of endosomal contents. 9, 33, 34 The presence of chloroquine has a notable effect on DNA delivery mediated by protamine alone, enhancing gene transfer nearly four-fold ( Figure 7 ). In contrast, no effect is observed on H2PO-mediated gene transfer, which consistently maintained a nearly five-fold higher gene delivery over protamine alone.
Discussion
We have demonstrated that the DNA/protein conjugate complex, H2PO, can be successfully targeted to breast cancer cells by means of the novel fusion protein, HerPBK10, which consists of a targeting ligand, an endosomolytic component and a DNA binding domain. Here, the receptor-binding motif of heregulin is used to mediate specific binding to breast cancer cells, and, as we have demonstrated previously, this ligand is rapidly endocytosed after cell binding. The penton protein used here does not participate in binding to an integrin recep- tor, but is essential, presumably, for lysis of the cellular endosome after internalization. Protamine protects the complexes from degradation by serum proteins. At the optimal ratios of protein to DNA, these complexes can transduce MDA-MB-453 human breast cancer cells in vitro by way of receptor-specific binding and internalization that is inhibited by free heregulin ligand. Accordingly, this method effectively targets gene delivery to cells expressing the receptor for heregulin. This is the first demonstration, to our knowledge, of targeting the adenoviral penton protein for gene delivery by way of recombinant fusion to a receptor-specific ligand. There are few examples of similar systems for comparison. The closest in similarity is GD5, which incorporated domains for DNA binding, membrane translocation, and targeting to HER2-expressing cells. 34 The GD5 fusion protein contained a Gal4 DNA binding sequence, which required the presence of Gal4 cis-elements in the plasmid payload for complex formation. Targeting of this complex was accomplished by the inclusion of a single chain antibody fragment directed to the ErbB2 (HER2) subunit. The diptheria toxin (DT) membrane translocation domain was included for endosomal penetration. The GD5 fusion protein enhanced delivery of a luciferase reporter gene to HER2-containing cells by 25-fold over DNA complexes lacking the fusion protein. These data are in agreement with our observation of up to a 34-fold higher luciferase activity in cells targeted by H2PO, in comparison to complexes lacking HerPBK10.
The ability of the penton protein to mediate gene transfer across the endosome membrane has been established previously, suggesting that the penton is sufficient for receptor-mediated endocytosis and vesicle lysis. 12, 35 The mechanism of endosome penetration, however, is still unclear. Studies of rhinovirus-mediated gene transfer suggest that viral fusogenic peptides form pores in the endosomal membrane in response to vesicle acidification, thus allowing the passage of endosomal contents into the cytosol. 36 Pore formation is the most plausible explanation for the membrane penetration activity of the DT translocation domain as well. 37 Lysis of the endosome by adenovirus, however, is likely due to a different mechanism since molecules of differing size are similarly released from endosomes in vitro by adenovirus, whereas the upper size exclusion by rhinovirus fusogenic peptides suggest the formation of pores of limiting size. This conceivably presents an advantage for gene transfer by penton proteins since they may override any size limitations imposed by channel-forming peptides.
A previous study has reported that the interaction of the penton protein with α v β 5 integrins is required for the promotion of endosomal penetration. 38 The data presented here suggest that integrin binding is not a determinant for penton-mediated gene transfer when the complexes are directed to a different receptor. Integrinspecific blocking peptides have a low to modest effect on gene delivery, suggesting that α v integrins contribute minimally to the gene transfer process by H2PO. In contrast, the nearly complete abolition of delivery by free heregulin suggests that heregulin receptor binding and internalization is the predominant mode of cell entry by H2PO. In comparison to 3PO complexes, which are directed to integrin receptors, the incorporation of the heregulin ligand markedly improves delivery to MDA-MB-453 cells. This may be due to the higher affinity of heregulin for its receptor in comparison to the affinity of the penton protein to α v integrins, in addition to the amplification of the heregulin receptor subunits on MDA-MB-453 cells. Furthermore, we observed no increase in gene delivery by H2PO compared with protamine alone on MDA-MB-231 cells, which lack heregulin receptors, again supporting the important contribution of the heregulin moiety.
Although it is shown here that HerPBK10 exhibits saturable cell binding, H2PO produced 10% of the GFP-positive cells and 13% of the luciferase activity of transduction by the nonspecific gene transfer reagent, lipofectin. The endosomolytic agent, chloroquine, does not affect H2PO-mediated transduction, suggesting that the complexes are not trapped in endosomes after receptormediated endocytosis. A post-cytosolic entry step, therefore, may account for the observed difference between HerPBK10 receptor binding and final gene expression by H2PO .
We have thus demonstrated the feasibility of producing a chimeric penton protein for nonviral targeted gene delivery. As a protein-based gene delivery system, the HerPBK10 fusion protein presented here lends itself to the testing and development of improved functions for eventual gene therapy use, while avoiding the complications associated with producing targeted viral vectors. As each domain of the fusion protein can be conceived as a separate entity providing a distinct function to the overall molecular complex, modular replacement of the targeting ligand may be possible, thus producing novel proteins targeted to other cell types. 
Materials and methods
Cells
DNA constructs
A common 5Ј oligonucleotide primer containing the sequence 5Ј-ATCGAAGGATCCATGCGGCGCGCGGCG ATGTAT-3Ј was used to amplify both wild-type and lysine-tagged penton sequences from a pJM17 adenoviral genome template. The sequences of the 3Ј primers are 5Ј-GCATCAGAATTCTCAAAAAGTGCGGCTCGATAG-3Ј (PB) and 5Ј-CATGAATTCA(TTT) 10 AAAAGTGCGGC TCGATAGGA-3Ј (PBK10). A BamHI restriction site was introduced in the 5Ј primer and an EcoRI restriction site was introduced in the 3Ј primers for in-frame insertion of both the wild-type and lysine-tagged pentons into the pRSET-A bacterial expression plasmid (Invitrogen, Carlsbad, CA, USA). This plasmid expresses the recombinant protein as an N-terminally histidine-tagged fusion for affinity purification by nickel chelate affinity chromatography. Polymerase chain reaction (PCR) amplification was used to add a sequence encoding a short polyglycine linker to the amino (N)-terminus of PBK10. The sequence encoding the linker contains a SacII restriction site for Gene Therapy additional cloning. The heregulin targeting ligand was produced by PCR amplification of the epidermal growth factor (EGF)-like domain of the heregulin gene 29 using a 5' oligonucleotide primer containing a BamHI site and a 3' primer containing a SacII site for cloning in-frame with PBK10. The targeting ligand was added to the lysinetagged construct to create HerPBK10 by ligating the PCR product just N-terminal to PBK10. Construction of Her and GFP-Her are described elsewhere. 29 HerK10 was created by PCR amplification of the Her construct using the existing 5' Her primer 29 and a 3' oligonucleotide primer containing the sequence 5'-ATGAATTCA(TTT) 10 AGA TCTACTTCCACCACTTCCACC-3'.
Protein expression and purification from bacteria
Overnight cultures of BL21(DE3)pLysS (Novagen, Madison, WI, USA) bacterial transformants were inoculated 1:50 in LB containing 0.1 mg/ml ampicillin and 0.034 mg/ml chloramphenicol. When cultures reached an absorbance reading of ෂ0.6 at an optical density wavelength of 600 nm (OD 600), cultures were induced with 1 mm IPTG and grown for a further 4 h at 37°C with shaking. Cultures were harvested and pelleted. Cell pellets were resuspended in lysis buffer (50 mm Na-phosphate, pH 8.0, 500 mm NaCl, 5-10 mm imidazole, 1 mm phenylmethylsulfonyl fluoride) and lysed by addition of 0.1% Triton X-100 and one cycle of freeze-thawing. Supernatants were recovered, added to Ni-NTA resin (Qiagen, Valencia, CA, USA) pre-equilibrated in lysis buffer, and incubated for 1 h on ice. The resin containing bound protein was washed with 10 ml of lysis buffer, then 6 ml of a solution of 50 mm Na-phosphate, pH 8.0, 500 mm NaCl; 60 mm imidazole, and protein was eluted with 2 ml of a solution of 50 mm Na-phosphate, pH 8.0, 500 mm NaCl, 400 mm imidazole. Proteins were desalted on YM-10 nominal molecular weight limit spin columns (Millipore, Bedford, MA, USA) and their concentrations measured using the BioRad protein quantitation assay (BioRad Laboratories, Hercules, CA, USA).
Protein detection
Denaturing polyacrylamide gel electrophoresis was performed in a discontinuous gel buffer system as previously described. Proteins were electrically transferred on to nitrocellulose using 39 mm glycine, 48 mm TrisHCl, 0.0375% SDS, 20% methanol in a BioRad semi-dry transfer cell set at constant voltage (15 V) for 30 min. Blots were blocked with 3% milk in phosphate-buffered saline (PBS 137 mm NaCl, 2.7 mm KCl, 4.3 mm Na 2 HPO 4 , 1.4 mm KH 2 PO 4 ). Anti-His Tag antisera (Sigma) was used at a 1:3000 dilution in blocking buffer. Anti-Ad5 antisera (Access Bio Medical, San Diego, CA, USA) was used at a 1:8000 dilution in blocking buffer. Antibody-antigen complexes were detected by incubation with horeseradish peroxidase (HRP) conjugated secondary antibodies (Sigma, St Louis, MO, USA), reaction with chemiluminescence detection reagents (Amersham Pharmacia Biotech, Piscataway, NJ, USA), and exposure to film (Hyperfilm ECL; Amersham Pharmacia Biotech).
Cell binding assay
Cells were treated with GFP-tagged proteins as described elsewhere. 29 Briefly, MDA-MB-453 cells grown to 75% confluency were lifted with PBS supplemented with 2 mm EDTA, centrifuged, washed three to four times with PBS, then added to PBS containing GFP-tagged proteins and 3% milk to reduce nonspecific binding. After a 1 h incubation on ice, cells were centrifuged, washed three to four times with PBS, resuspended in 0.5 ml PBS and measured by FACScan.
DNA mobility shift assays DNA was mixed with proteins at the indicated ratios in HEPES-buffered saline (HBS, 150 mm NaCl, 20 mm HEPES, pH 7.3) for 30 min at room temperature in a total volume of 10 l. After incubation, 2 l of sample dye was added to the mixtures, mixes were loaded on a 0.8% agarose gel, and electrophoresed at 50 V. Gels were stained with ethidium bromide after electrophoresis to visualize DNA bands. The 1 kb ladder was obtained from Life Technologies, Rockville, MD, USA.
DNA protection assay
Plasmid and proteins were added together at various ratios in a total volume of 20 l and incubated at room temperature for 30 min. Four l of active (non-heatinactivated) fetal bovine serum were added to each mix and mixtures were incubated at 37°C. SDS at a 1% final concentration was added to each mix to release the proteins from the DNA. Four l of sample dye was added to each mix, and mixtures were electrophoresed on agarose gels as described earlier.
Cell delivery assays
Cells were grown on 24-well dishes to approximately 75% confluency. Proteins and plasmids (3.5 g) were incubated together at various ratios at room temperature for 30 min in 0.3 ml of adhesion buffer (DMEM, 2 mm MgCl 2 , 20 mm HEPES), then added to cell monolayers. Cells were exposed to mixes for 3-5 h at 37°C, 5% CO 2 , before the addition of complete serum. Cells were trypsinized and counted by FACS, where indicated, and using a hemocytometer under UV light microscopy to determine the percentage and absolute numbers of GFPpositive cells.
UV microscopy
An Olympus IMT-2 inverted microscope fitted with an FITC filter was used to visualize GFP-positive cells. Photomicrographs were taken at 4× and 10× magnification.
FACS analysis
Where indicated, 5000-10 000 events are counted on a Becton Dickinson FACScan analyzer (Becton Dickinson, Franklin Lakes, NJ, USA) using a 15 mW air-cooled argon laser set at 488 nm and recorded with a 530 nm emission filter in the FL1 emission channel. Cell populations are represented on a FACS histogram plotting green fluorescence intensity on a logarithmic scale against cell number. Fluorescence intensity of cell populations is indicated by a shift to the right of the histographical plots of treated cells. Fluorescence enhancement was determined by obtaining the number of gated fluorescent events for untreated and treated cells.
Luciferase assay
Luciferase activity was determined using the Steady-Glo luciferase assay system (Promega) following the manufacturer's instructions. Briefly, to each well was added an equivalent volume of Steady-Glo reagent. The dish was incubated at room temperature for 5 min to allow lysis, and wells were read directly at 5 s per well using an MLX microtiter plate luminometer (Dynex Technologies, Chantilly, VA, USA) using the Glow Endpoint assay type set on autogain. Protein concentrations were determined from aliquots of lysed samples using the BioRad protein quantification assay (BioRad Laboratories).
